CD19 and myasthenia gravis: Recently, a patient with AChR-MG previously refractory to rituximab, bortezomib, and other immunosuppressive agents was treated with anti-CD19 CAR T cells, resulting in improvement of disease activity and a 70% drop in anti-AChR autoantibody titer within 2 months of infusion, suggesting that a substantial proportion of pathogenic autoantibodies in MG are made by short-lived plasma cells that can be targeted by depleting precursor CD19-expressing memory B cells (2, 4).